Profile: Jan Leschly - Cash drives the need to be number one

The SmithKline boss used to say big wasn't necessary. It is now, writes Dana Rubin

JAN LESCHLY has been a vocal proponent of the view that massive mergers and acquisitions are not a panacea for the problems of the drug industry.

So it's ironic that the 57-year-old chief executive of SmithKline Beecham should be the one to steer his drug and healthcare company towards a merger with American Home Products. Such a merger would create the world's largest drug company.

Just a few years ago, when some of the giants of the pharmaceuticals industry were combining forces, it was Leschly who cautioned against the dangers of relying on acquisitions to create growth. The surest route to prosperity, he said, was not takeovers, but new products.

"It doesn't matter how big you are," he said at the time. "I don't believe you have to have 10 per cent of the drugs market to prosper," referring to a comment by Sir Richard Sykes, then chief executive of SmithKline's rival Glaxo, which merged with Wellcome in 1995. So what has happened to change Leschly's mind?

The cost of developing new drugs, for one thing. In recent years the cost of new technologies needed to develop drugs has skyrocketed. It now takes at least $400m (pounds 240m) to $500m to bring a new drug to market.

"He's been hindered by his cash limitations," says Mark Becker, pharmaceuticals analyst at JP Morgan Securities in London. Becker said SmithKline now spends about $1bn a year on research and development, about half the spending of European rivals such as Novartis, Roche Holding and Glaxo Wellcome. "He needs to increase his R&D substantially," says Becker.

If the merger goes ahead, Leschly - a former Danish tennis champion who lives in the US - would almost certainly become chief executive of the combined companies. He could not be reached for comment.

Since becoming SmithKline chief executive in 1994, Leschly has focused on new drug development, pushing the company into the promising but so far unprofitable field of genetic research. Last May, SmithKline committed $125m to a collaboration with the biotech firm Human Genome Sciences of Rockville, Maryland.

Leschly, who played in 16 Wimbledon tennis tournaments and the Davis Cup before going into business, has won praise for his solid corporate leadership and uncompromising sense of competition.

"The best argument wins and there is no mercy," he once told an interviewer. "But some people don't understand that you play the game and afterwards you go for a beer and you're friends."

Leschly has impressed the investment community with his intense if somewhat hyperactive presentations. "He is a very inspirational person," says Jami Rubin, a pharmaceuticals analyst at Schroder & Co in New York. "You want to buy his stock. You want to work for the guy. You believe in what he's saying. He walks in a room and the place lights up."

He grew up in Odense, Denmark's second largest city, one of two sons. Older brother Peter taught him to play tennis when he was six, and within a few years he was beating his brother. He travelled the world on the tennis circuit but never got further than the quarter-finals. A family shock led him to give up the game - his brother suffered a mysterious fever and was left paralysed. Now in a wheelchair, Peter Leschly is a businessman in Denmark with a number of corporate directorships, including hi-fi firm Bang & Olufsen.

While playing tennis, Leschly had trained as a pharmacist in Copenhagen and received an MBA there. In 1972 he joined the Danish pharmaceuticals company Novo Nordisk, and in three years was president of its pharmaceuticals division.

Through a joint venture with the US company Squibb, Leschly met executives at that company and in 1979 he was asked to join them as vice-president of commercial development. His wife Lotte gave up her dental practice in Denmark, and she and their four sons moved with him to Princeton, New Jersey.

Leschly was said to be in line for the chairmanship at Squibb when the company was sold to Bristol-Myers. Instead he found himself without a job, a predicament reportedly sweetened by a payoff of several million dollars. He was 49. He once described his choices then as: "I could buy an island. Not me. I could start my own business. Or I could go back to corporate life.''

While weighing these options, he sat in on a few classes in philosophy and religion at Princeton university, where his son was studying. It turned out to be a clever public relations move, conferring on Leschly a reputation as something of a philosopher-king.

The following year he was recruited to head the pharmaceutical division of the newly-created SmithKline Beecham, the result of a merger between London-based Beecham and SmithKline Beckman of Philadelphia. It was understood that he was in line for the top job, and when Bob Bauman retired as chief executive in 1994, Leschly took over. He has been credited with making the merger work, restructuring the company, bringing in new products and moving boldly on acquisitions. Since he became chief executive, SmithKline shares have climbed from 350p to 721p, outperforming every other drug stock.

In his first five months, Leschly made two major purchases - Sterling Winthrop, maker of painkillers and other drugs, for $2.9bn, and Diversified Pharmaceutical Services, a large drug wholesaler, for $2.3bn. The first has been regarded as a far more successful buy. He also tried to buy American Cyanamid but was outbid by American Home.

In recent years SmithKline has turned to emerging technologies such as bioinformatics, combinatorial chemistry and smart screening in the search for new drugs. Leschly has said the industry can no longer wait for academia and biotech companies to develop new drugs and then buy the rights: companies must get involved at early stages of research through partnerships and alliances. He says he signs new deals just about every week although, to be fair, most of his competitors do the same.

SmithKline has done extremely well with its anti-depressant Paxil, its most successful drug in growth terms. It has also had good results with Relafen, an arthritis painkiller. Two drugs with billion-dollar potential are in the pipeline: Idoxifine, for osteoporosis and breast cancer, and Avandia, a diabetes drug.

This success, actual and potential, may lie behind his interest in merging with AHP. "Because his pipeline is so robust, he has to increase his marketing effort quite a bit," says Becker. If Jan Leschly can realise all his sales potential, invest in marketing and double R&D, he will be doing very well.

Copyright: IOS & Bloomberg

Start your day with The Independent, sign up for daily news emails
News
Nick Clegg on the campaign trail in Glasgow on Wednesday; he says education is his top priority
peopleNick Clegg remains optimistic despite dismal Lib Dem poll ratings
Arts and Entertainment
Buttoned up: Ryan Reynolds with Helen Mirren in ‘Woman in Gold’
filmFor every box-office smash in his Hollywood career, there's always been a misconceived let-down. Now he says it's time for a reboot
News
people
News
Actress Julianne Moore wins the Best Actress in a Leading Role Award for 'Still Alice' during the 87th Annual Academy Awards in Hollywood, California
people
Sport
Ross Barkley
footballPaul Scholes says it's time for the Everton playmaker to step up and seize the England No 10 shirt
News
'We will fix it': mice in the 1970s children’s programme Bagpuss
science
Life and Style
2 Karl Lagerfeld and Choupette
fashion
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Graduate Recruitment Resourcer

£20000 per annum + commission: SThree: Sthree have an exciting opportunity for...

Recruitment Genius: Telesales Executive - OTE £32,000+

£18000 - £32000 per annum: Recruitment Genius: A Telesales Executive is requir...

Ashdown Group: Marketing Manager - B2B, Corporate - City, London

£45000 - £50000 per annum + benefits : Ashdown Group: A highly successful, glo...

Neil Pavier: Commercial Analyst

£50,000 - £55,000: Neil Pavier: Are you a professionally qualified commercial ...

Day In a Page

War with Isis: Iraq declares victory in the battle for Tikrit - but militants make make ominous advances in neighbouring Syria's capital

War with Isis

Iraq declares victory in the battle for Tikrit - but militants make make ominous advances in neighbouring Syria
Scientists develop mechanical spring-loaded leg brace to improve walking

A spring in your step?

Scientists develop mechanical leg brace to help take a load off
Peter Ackroyd on Alfred Hitchcock: How London shaped the director's art and obsessions

Peter Ackroyd on Alfred Hitchcock

Ackroyd has devoted his literary career to chronicling the capital and its characters. He tells John Walsh why he chose the master of suspense as his latest subject
Ryan Reynolds interview: The actor is branching out with Nazi art-theft drama Woman in Gold

Ryan Reynolds branches out in Woman in Gold

For every box-office smash in Ryan Reynolds' Hollywood career, there's always been a misconceived let-down. It's time for a rethink and a reboot, the actor tells James Mottram
Why Robin Williams safeguarded himself against a morbid trend in advertising

Stars safeguard against morbid advertising

As film-makers and advertisers make increasing posthumous use of celebrities' images, some stars are finding new ways of ensuring that they rest in peace
The UK horticulture industry is facing a skills crisis - but Great Dixter aims to change all that

UK horticulture industry facing skills crisis

Great Dixter manor house in East Sussex is encouraging people to work in the industry by offering three scholarships a year to students, as well as generous placements
Hack Circus aims to turn the rule-abiding approach of TED talks on its head

Hack Circus: Technology, art and learning

Hack Circus aims to turn the rule-abiding approach of TED talks on its head. Rhodri Marsden meets mistress of ceremonies Leila Johnston
Sevenoaks is split over much-delayed decision on controversial grammar school annexe

Sevenoaks split over grammar school annexe

If Weald of Kent Grammar School is given the go-ahead for an annexe in leafy Sevenoaks, it will be the first selective state school to open in 50 years
10 best compact cameras

A look through the lens: 10 best compact cameras

If your smartphone won’t quite cut it, it’s time to invest in a new portable gadget
Paul Scholes column: Ross Barkley played well against Italy but he must build on that. His time to step up and seize that England No 10 shirt is now

Paul Scholes column

Ross Barkley played well against Italy but he must build on that. His time to step up and seize that England No 10 shirt is now
Why Michael Carrick is still proving an enigma for England

Why Carrick is still proving an enigma for England

Manchester United's talented midfielder has played international football for almost 14 years yet, frustratingly, has won only 32 caps, says Sam Wallace
Tracey Neville: The netball coach who is just as busy as her brothers, Gary and Phil

Tracey Neville is just as busy as her brothers, Gary and Phil

The former player on how she is finding time to coach both Manchester Thunder in the Superleague and England in this year's World Cup
General Election 2015: The masterminds behind the scenes

The masterminds behind the election

How do you get your party leader to embrace a message and then stick to it? By employing these people
Machine Gun America: The amusement park where teenagers go to shoot a huge range of automatic weapons

Machine Gun America

The amusement park where teenagers go to shoot a huge range of automatic weapons
The ethics of pet food: Why are we are so selective in how we show animals our love?

The ethics of pet food

Why are we are so selective in how we show animals our love?